Benefit Reimbursement Rate for FY2026 Revised Upward by 0.60% (April 30, 2026) – Social Insurance Research Institute

News Highlights

The Social Insurance Research Institute has reported that the benefit reimbursement rate for FY2026 has been decided at a positive 0.60%. This revision, announced on April 30, 2026, may impact the financial performance of medical institutions.

Perspective from M&A Medical Editorial Department

Looking solely at the 0.60% increase in the benefit reimbursement rate, it might seem that the contribution to improving the management of many medical institutions, especially small clinics and private practices, will be limited. However, it is important to view this revision rate in conjunction with the issue of succession. For example, when a medical institution where the chairman/director is approaching 60 years old and is struggling with a lack of successor considers third-party succession rather than closure or廃業 (going out of business), this positive revision can serve as one piece of information indicating the “possibility of business continuity.” Particularly for small to medium-sized medical institutions that bear the responsibility of regional healthcare, even a slight positive revision can be a factor in succession decisions when planning for future financial projections. In the field of medical M&A brokerage, it is essential to combine such macro-level revision trends with the micro-level management and succession challenges faced by individual medical institutions to propose optimal solutions.

Points Highlighted by This News

• Is the 0.60% increase in the benefit reimbursement rate limited in its effect on improving the management of small medical institutions?
• For medical institutions lacking successors, even a slight positive revision can be a factor in succession decisions.
• Impact on financial projections for small to medium-sized medical institutions supporting regional healthcare.
• The importance of M&A proposals that combine macro-level revision trends with micro-level management challenges.

Practical Questions Arising from This News

• To which specific medical departments or services will this 0.60% revision rate have a significant impact?
• How can clinics lacking successors utilize this revision rate to successfully achieve third-party succession?
• Are there any economic indicators other than the benefit reimbursement rate that medical institutions should pay attention to when making future financial projections?

If You Feel “Should I Consult Too?”

If your institution is facing succession issues and you are exploring options other than closure or going out of business, please consider this news of a 0.60% increase in the benefit reimbursement rate as an opportunity to explore the possibility of business continuity. Even a slight positive revision can lead to increased attractiveness for third-party succession. We recommend first organizing your institution’s current situation and future vision, and then discussing succession possibilities with experts.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a certified M&A support institution by the Small and Medium Enterprise Agency, with a complete success fee system. Consultations are accepted with strict confidentiality. Free consultation here